Innovative Antibody Drug Conjugate for Gastrointestinal Cancers: ArriVent BioPharma and Lepu Biopharma Enter Exclusive License Agreement for MRG007
New Partnership between ArriVent BioPharma, Inc. and Lepu Biopharma Co., Ltd Exciting News in the Biopharmaceutical Industry In a major development in the world of biopharmaceuticals, ArriVent BioPharma, Inc. has recently announced an exclusive license agreement with Lepu Biopharma Co., Ltd for MRG007, an antibody-drug conjugate (ADC) targeting gastrointestinal cancers. This partnership marks a significant…